Merck KGaA’s Out-Licensing Agreement for Osteoarthritis Asset Sprifermin

McDermott Will & Emery represented Merck KGaA on the deal.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, through its subsidiary Ares Trading S.A., announced a venture-capital style investment in and its licensed spinoff of global intellectual property rights for a regenerative monoclonal antibody known as “Sprifermin”, being investigated to treat osteoarthritis, to High Line Bio, Inc., a new US-based company formed for this purpose by TrialSpark, which uses its tech-enabled platform to run end-to-end clinical trials.

This transaction continues the strategic evolution of Merck KGaA, Darmstadt, Germany’s  immunology pipeline. 

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live.

The McDermott team was led by Albert Sokol (Picture) and included Jennifer Bock, Rebecca Dufur, Robert Cohen, David Levine, Michael Bruno, Keith Hagan and Michael Wilder.

Involved fees earner: Jennifer Bock – McDermott Will & Emery; Michael Bruno – McDermott Will & Emery; Robert Cohen – McDermott Will & Emery; Rebecca Dufur – McDermott Will & Emery; Keith Hagan – McDermott Will & Emery; David Levine – McDermott Will & Emery; Albert Sokol – McDermott Will & Emery; Michael Wilder – McDermott Will & Emery;

Law Firms: McDermott Will & Emery;

Clients: Merck KGaA;